封面
市場調查報告書
商品編碼
1058842

細胞株開發的全球市場(2021年~2028年)

Global Cell Line Development Market - 2021-2028

出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 約2個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

本報告提供全球細胞株開發市場相關調查分析,提供市場動態,產業分析,市場分析,競爭情形等系統性資訊。

目錄

第1章 全球細胞株開發市場調查手法和範圍

  • 調查手法
  • 調查的目的和調查範圍

第2章 全球細胞株開發市場-市場定義和概要

第3章 全球細胞株開發市場-摘要整理

  • 市場明細:各細胞株類型
  • 市場明細:各應用領域
  • 市場明細:各供給來源
  • 市場明細:各產品
  • 市場明細:各終端用戶
  • 市場明細:各地區

第4章 全球細胞株開發市場-市場動態

  • 影響市場的要素
    • 促進因素
    • 阻礙因素
    • 市場機會
    • 影響分析

第5章 全球細胞株開發市場-產業分析

  • 波特的五力分析
  • 供應鏈分析
  • 價格分析
  • 法規分析
  • 償付分析

第6章 全球細胞株開發市場-COVID-19分析

  • 市場上的COVID-19分析
    • COVID-19前的市場方案
    • 目前COVID-19市場方案
    • COVID-19後的市場方案/未來市場方案
  • COVID-19的價格的動態
  • 需求與供給的頻譜
  • 政府在COVID-19疫情下的市場相關措施
  • 製造商策略性舉措
  • 結論

第7章 全球細胞株開發市場:各細胞株類型

  • 簡介
    • 市場規模分析,及與前一年同期比較成長分析(%):各細胞株類型
    • 市場魅力指數:各細胞株類型
  • 第一代細胞株*
    • 簡介
    • 市場規模分析(100萬美元)(2019年~2028年),及與前一年同期比較成長分析(%)(2020年~2028年)
  • 連續細胞系
  • 融合瘤
  • 重組細胞株

第8章 全球細胞株開發市場:各應用領域

  • 簡介
    • 市場規模分析,及與前一年同期比較成長分析(%):各應用領域
    • 市場魅力指數:各應用領域
  • 生物生產*
    • 簡介
    • 市場規模分析(100萬美元)(2019年~2028年),及與前一年同期比較成長分析(%)(2020年~2028年)
  • 組織工程再生醫療
  • 毒性實驗
  • 研究
  • 藥物研發

第9章 全球細胞株開發市場:各供給來源

  • 簡介
    • 市場規模分析,及與前一年同期比較成長分析(%):各供給來源
    • 市場魅力指數:各供給來源
  • 哺乳類細胞株*
    • 簡介
    • 市場規模分析(100萬美元)(2019年~2028年),及與前一年同期比較成長分析(%)(2020年~2028年)
  • 非哺乳類細胞株

第10章 全球細胞株開發市場:各產品

  • 簡介
    • 市場規模分析,及與前一年同期比較成長分析(%):各產品
    • 市場魅力指數:各產品
  • 試劑和培養基*
    • 簡介
    • 市場規模分析(100萬美元)(2019年~2028年),及與前一年同期比較成長分析(%)(2020年~2028年)
  • 設備
  • 結束細胞
  • 其他

第11章 全球細胞株開發市場:各終端用戶

  • 簡介
    • 市場規模分析,及與前一年同期比較成長分析(%):各終端用戶
    • 市場魅力指數:各終端用戶
  • 生物科技企業*
    • 簡介
    • 市場規模分析(100萬美元)(2019年~2028年),及與前一年同期比較成長分析(%)(2020年~2028年)
  • 學術及研究
  • 其他

第12章 全球細胞株開發市場:各地區

  • 簡介
    • 市場規模分析(100萬美元)(2019年~2028年),及與前一年同期比較成長分析(%)(2020年~2028年):各地區
    • 市場魅力指數:各地區
  • 北美
  • 歐洲
  • 南美
  • 亞太地區
  • 中東和非洲

第13章 全球細胞株開發市場-競爭情形

  • 主要的發展與策略
  • 企業佔有率分析
  • 產品的基準

第14章 全球細胞株開發市場-企業簡介概要

  • GE Healthcare*
    • 企業概要
    • 產品系列及說明
    • 主要亮點
    • 財務概要
  • American Type Culture Collection
  • Lonza Group AG
  • Thermo Fisher Scientific Inc
  • Sigma-Aldrich Corporation
  • Selexis SA
  • Promega Corporation
  • Corning Inc
  • WuXiApp Tec Inc
  • Sartorious AG

第15章 全球細胞株開發市場-DataM

  • 附錄
  • 關於本公司·服務
  • 諮詢方式
簡介目錄
Product Code: DMBT4657

Market Overview

The Global "Cell line Development Market" is Predicted to reach at a CAGR of XX% during the forecast period (2021-2028).

The cell line is a well-established cell culture in which the cells multiply in the appropriate growth media and space. Distinct types of cells are used to create different cell lines. Cell lines allow for gradual changes in cell structure, physiology, and genetic makeup in a controlled setting.

Market Dynamics

The increasing use of regenerative treatments, rising cancer occurrence around the world, and soaring R&D investments by pharmaceutical and biotechnology businesses are all contributing to the cell line development market's growth. Moreover, ongoing research in drug discovery efforts is expected to fuel market expansion during the forecast period.

The increase in prevalance of cancer cases in the market will drive the market growth

Because the global cancer burden is expanding, cancer treatments must be tailored to regional and national goals. According to the WCRF, there were an estimated 18 million cancer cases worldwide in 2018, with 9.5 million males and 8.5 million women affected.

Lung and breast cancers are the most frequent cancers, accounting for 12.3 percent of all new cases diagnosed in 2018. According to the WCRF, colorectal malignancy was the third most frequent cancer in 2018, with 1.8 million new cases.

Many factors contribute to the rising cancer burden, including population increase and aging and the changing prevalence of various cancers linked to social and economic developments. Cancer has also been linked to one's way of life.

The figures above shows that cancer has a high global burden, which is projected to drive the cell line development market extension. There is a growing desire for innovative therapies to treat cancer. Regenerative medicines can replace or mend tissues and organs that have been destroyed by aging, disease, or trauma and assist in normalizing congenital abnormalities. Over the previous quarter-century, a tissue engineering industry has emerged, which has expanded into the broader field of regenerative medicine. Engineering sciences are being used to produce clinical therapies for the maintenance, repair, replacement, and augmentation of biological processes in regenerative medicine, which is a fast emerging interdisciplinary subject. The generation of cell lines is an essential and inextricable aspect of this area since it aids in the understanding of how to treat a wide range of medical disorders, from broken bones to neurological diseases. Regenerative medicines also use cell-based models, which could aid researchers in developing early-intervention treatments for degenerative diseases and catastrophic injuries. As a result, the growing use of regenerative treatments will fuel demand for cell line development in the future years. This contributes to the growth of the global cell line development market.

High capital investment and complexity associated with the cell development process is likely to hamper the market growth

Every stage of the CLD workflow can be arduous and time-consuming, limiting the cell line development market's growth. Furthermore, the possibility of contamination, misidentification, and random alternations in cell line creation impede the market's expansion.

COVID-19 Impact Analysis

Over the projection period, the increased prevalence of COVID-19 is expected to impact cell line development market growth. The majority of pharmaceutical businesses have suffered considerable losses due to the coronavirus outbreak, which has hampered the cell line development market. The COVID-19 pandemic has had a remarkable influence on the global economy; this has significantly impacted production processes and demand across multiple verticals and disrupted the supply chain. During the initial phase of the COVID, many businesses ceased manufacturing and supply operations. However, the current COVID-19 situation is expected to return to normalcy as medical professionals and health authorities in the countries take the necessary steps to combat the virus. Furthermore, pharmaceutical companies and research institutions worldwide have focused their efforts on developing a vaccine for COVID-19, putting the development of other therapeutics on hold.

Segment Analysis

The mammalian cell development segment is expected to grow at the fastest CAGR during the forecast period (2021-2028)

Mammalian cells are estimated to account for majority of the market share over the forecast period. The increased usage of a mammalian source to manufacture monoclonal antibodies is a major factor driving the cell line development market (mAbs). The need to express complex proteins in a human-like manner is also predicted to promote product uptake in the coming years.There has been a surge in the of FDA-approved recombinant protein therapies. According to the National Institute of Health, the US Food and Drug Administration (FDA) approves more than 15 innovative recombinant protein treatments each year. Furthermore, the expiration of branded pharmaceuticals has prompted the development of biosimilars. As a result, the demand for cell line creation is increasing. The methotrexate (MTX) amplification method or the glutamine synthetase (GS) system are used by most biopharmaceutical businesses that create mammalian cell lines. Mammalian cell line cell clones are highly heterogeneous, and many cell clones must be screened to identify rare stable high producer cell clones. Several advances in mammalian cell line development have been made to make the screening process easier, making it the preferred source for cell line development. Furthermore, the need for cell line creation is expected to be fueled by enhanced cell engineering and expression methods to develop this source. There are roughly 4,000 mammalian cell lines available for biologics research and manufacture. As a result of advancements in mammalian cell lines, the segment is expected to grow steadily in the future.

Geographical Analysis

North America region holds the largest market share of the global cell line development market

North America accounted for the majority of the share of the global cell line development market. The United States has a better healthcare infrastructure and presence of major companies in the country are contributing to the dominance of this region. In addition, the US government's funding for accelerating research in the biotechnology and pharmaceuticals industries has boosted the demand for cell line creation. Furthermore, the presence of many key players in North America is a major factor driving market growth.

However, The Asia-Pacific region is expected to rise rapidly in the global cell line development market. The Asia-Pacific regional market is expected to grow rapidly due to rising government and private-sector healthcare spending. In India, for example, the Department of Scientific and Industrial Research (DSIR)and Department of Science and Technology (DST), Department of Biotechnology (DBT) regulate and set guidelines for biotechnology products. These organizations provide guidelines for manufacturing or technology transfer and generate manpower for production and raise funds.

Competitive Landscape

The cell line development market is highly competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include American Type Culture Collection, Lonza Group AG, Thermo Fisher Scientific Inc, GE Healthcare, Sigma Aldrich Corporation ,Selexis SA, Promega Corporation, Corning Inc, WuXiApp Tec Inc, Sartorious AG.

The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the blood and blood products market globally. For instance in Oct 2019, ATCC (US) has introduced a portfolio of exosomes (extracellular vesicles) derived from human cells to be used as reference materials or standards in various research applications. Researchers' first two exosomes are derived from the A549 non-small cell lung cancer (NSCLC) cell line and hTERT-immortalized mesenchymal stem cells.

Key Developments

In Oct 2019, The American Type Culture Collection has launched a mouse cell line authentication service (NIST). This collaboration has aided the corporation in expanding both its cell line business portfolio and its existing customer base.

In Feb 2017, Lonza and Sanofi have formed strategic cooperation to create mammalian cell culture facilities in Switzerland to manufacture monoclonal antibodies. The company was able to expand regionally and generate more money due to this strategy.

In 2018, Denali Therapeutics (US) and Lonza (Switzerland) have cooperated to research and manufacture biologic medicines using Lonza's GS Xceed cell line development technology. The major players engage in strategic partnerships, product launches, and joint ventures.

In Sep 2020, Octapharma (Switzerland), a major manufacturer of human therapeutic proteins, selected Genedata Selector (Switzerland) as its key computational platform to expedite next-generation sequencing-based cell line development and cell culture optimization procedures. The partnership was carried out to save development time and improve efficiency.

In November 2017, Lonza Group (Switzerland) launched a Multiplex Cell line culture that uses a GS Xceed Gene Expression System to test multiple drug candidates at an early developmental stage, saving 4 to 6 months that would otherwise be required in a traditional development program.

GE Healthcare

Overview: GE Healthcare's Edison intelligence platform enables physicians to make faster, more informed decisions via intelligent devices, data analytics, applications, and services.

Product Portfolio:

Promosome mammalian cell lines: Promosome's mammalian cell line creation technologies, which aim to boost protein expression in mammalian cells.

Why Purchase the Report?

Visualize the composition of the global cell line development market segmentation by types of cell lines, application, source, product, and end user, and region highlighting the key commercial assets and players.

Identify commercial opportunities in global cell line development market by analyzing trends and co-development deals.

Excel data sheet with thousands of data points of global cell line development market- level 4/5 segmentation.

PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

Product mapping in excel for the key product of all major market players

The global cell line development market report would provide an access to an approximately 40+ market data table, 45+ figures and 180 pages.

Target Audience

Service Providers/ Buyers

Industry Investors/Investment Bankers

Education & Research Institutes

Research Professionals

Emerging Companies

Manufacturers

Market Segmentation

Global Cell Line Development Market- By Types of Cell Lines

Primary Cell Lines

Continuous Cell Lines

Hybridomas

Recombinant Cell Lines

Global Cell Line Development Market- By Application

Bioproduction

Tissue Engineering & Regenerative Medicines

Toxicity Testing

Research

Drug Discovery

Global Cell Line Development Market- By Source

Mammalian Cell Lines

Non-Mammalian Cell Line

Global Cell Line Development Market- By Product

Reagent and Media

Equipment

Finished Cells

Others

Global Cell Line Development Market- By End User

Biotech Companies

Academics and Research Institutes

Others

Global Cell Line Development Market- By Region

North America

Europe

Asia-Pacific

Middle East & Africa

South America

Table of Contents

1. Global Cell Line Development Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Global Cell Line Development Market- Market Definition and Overview

3. Global Cell Line Development Market- Executive Summary

  • 3.1. Market Snippet by Type of Cell Lines
  • 3.2. Market Snippet by Application
  • 3.3. Market Snippet by Source
  • 3.4. Market Snippet by Product
  • 3.5. Market Snippet by End User
  • 3.6. Market Snippet by Region

4. Global Cell Line Development market- Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Growing biopharmaceutical industry
      • 4.1.1.2. Rising demand for monoclonal antibodies and cancer therapeutic
      • 4.1.1.3. Growing production of biosimilars due to the patent expiring of branded therapeutics
    • 4.1.2. Restraints:
      • 4.1.2.1. Strict regulations
      • 4.1.2.2. Time taking process
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Global Cell Line Development Market- Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Reimbursement Analysis

6. Global Cell Line Development Market- COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. Global Cell Line Development Market- By Types of Cell Lines

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of Cell Lines Segment
    • 7.1.2. Market Attractiveness Index, By Type of Cell Lines Segment
  • 7.2. Primary Cell Lines*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 7.3. Continuous Cell Lines
  • 7.4. Hybridomas
  • 7.5. Recombinant Cell Lines

8. Global Cell Line Development Market- By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application
  • 8.2. Bioproduction*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 8.3. Tissue Engineering Regenerative Medicines
  • 8.4. Toxicity Testing
  • 8.5. Research
  • 8.6. Drug Discovery

9. Global Cell Line Development Market- By Source

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Source
    • 9.1.2. Market Attractiveness Index, By Source
  • 9.2. Mammalian Cell Lines*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 9.3. Non -Mammalian Cell Line

10. Global Cell Line Development Market- By Product

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 10.1.2. Market Attractiveness Index, By Product
  • 10.2. Reagent and Media*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 10.3. Equipment
  • 10.4. Finished Cells
  • 10.5. Others

11. Global Cell Line Development Market- By End User

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 11.1.2. Market Attractiveness Index, By End User Segment
  • 11.2. Biotech Companies*
    • 11.2.1. Introduction
    • 11.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 11.3. Academics and Research Institutes
  • 11.4. Others

12. Global Cell Line Development Market- By Region

  • 12.1. Introduction
    • 12.1.1. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028, By Region
    • 12.1.2. Market Attractiveness Index, By Region
  • 12.2. North America
    • 12.2.1. Introduction
    • 12.2.2. Key Region-Specific Dynamics
    • 12.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of Cell Lines
    • 12.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 12.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Source
    • 12.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 12.2.7. Market Size Analysis ,and Y-o-Y Growth Analysis (%), By End User
    • 12.2.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 12.2.8.1. U.S.
      • 12.2.8.2. Canada
      • 12.2.8.3. Mexico
  • 12.3. Europe
    • 12.3.1. Introduction
    • 12.3.2. Key Region-Specific Dynamics
    • 12.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of Cell Lines
    • 12.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 12.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Source
    • 12.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 12.3.7. Market Size Analysis ,and Y-o-Y Growth Analysis (%), By End User
    • 12.3.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 12.3.8.1. Germany
      • 12.3.8.2. U.K.
      • 12.3.8.3. France
      • 12.3.8.4. Italy
      • 12.3.8.5. Spain
      • 12.3.8.6. Rest of Europe
  • 12.4. South America
    • 12.4.1. Introduction
    • 12.4.2. Key Region-Specific Dynamics
    • 12.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of Cell Lines
    • 12.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 12.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Source
    • 12.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 12.4.7. Market Size Analysis ,and Y-o-Y Growth Analysis (%), By End User
    • 12.4.8.
    • 12.4.9. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 12.4.9.1. Brazil
      • 12.4.9.2. Argentina
      • 12.4.9.3. Rest of South America
  • 12.5. Asia Pacific
    • 12.5.1. Introduction
    • 12.5.2. Key Region-Specific Dynamics
    • 12.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of Cell Lines
    • 12.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 12.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Source
    • 12.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 12.5.7. Market Size Analysis ,and Y-o-Y Growth Analysis (%), By End User
    • 12.5.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 12.5.9. China
      • 12.5.9.1. India
      • 12.5.9.2. Japan
      • 12.5.9.3. Australia
      • 12.5.9.4. Rest of Asia Pacific
  • 12.6. Middle East and Africa
    • 12.6.1. Introduction
    • 12.6.2. Key Region-Specific Dynamics
    • 12.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of Cell Lines
    • 12.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 12.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Source
    • 12.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 12.6.7. Market Size Analysis ,and Y-o-Y Growth Analysis (%), By End User

13. Global Cell Line Development Market- By Competitive Landscape

  • 13.1. Key Developments and Strategies
  • 13.2. Company Share Analysis
  • 13.3. Product Benchmarking

14. Global Cell Line Development Market- By Company Profiles

  • 14.1. GE Healthcare*
    • 14.1.1. Company Overview
    • 14.1.2. Product Portfolio and Description
    • 14.1.3. Key Highlights
    • 14.1.4. Financial Overview
  • 14.2. American Type Culture Collection
  • 14.3. Lonza Group AG
  • 14.4. Thermo Fisher Scientific Inc
  • 14.5. Sigma-Aldrich Corporation
  • 14.6. Selexis SA
  • 14.7. Promega Corporation
  • 14.8. Corning Inc
  • 14.9. WuXiApp Tec Inc
  • 14.10. Sartorious AG

LIST NOT EXHAUSTIVE

15. Global Cell Line Development Market- By DataM

  • 15.1. Appendix
  • 15.2. About Us and Services
  • 15.3. Contact Us